Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)

被引：21

作者：

Mildner, Finn ^{[1
,3
]}

Sopper, Sieghart ^{[1
,3
]}

Amann, Arno ^{[1
,3
]}

Pircher, Andreas ^{[1
]}

Pall, Georg ^{[1
]}

Koeck, Stefan ^{[1
,3
]}

Naismith, Erin ^{[1
]}

Wolf, Dominik ^{[1
,2
,3
]}

Gamerith, Gabriele ^{[1
,3
]}

机构：

[1] Med Univ Innsbruck, Internal Med Hematol & Oncol 5, Anichstr 35, A-6020 Innsbruck, Austria

[2] Univ Hosp Bonn UKB, Internal Med Oncol Hematol Immunoncol Rheumatol 3, Venusberg Campus 1, D-53127 Bonn, Germany

[3] Tiroler Krebsforsch Inst TKFI, Innrain 66, A-6020 Innsbruck, Austria

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷

关键词：

Immunotherapy; Liquid biopsy; NSCLC; Biomarker; Longitudinal monitoring; Tumor-immune microenvironment; CIRCULATING TUMOR-CELLS; PERIPHERAL-BLOOD; PD-L1; EXPRESSION; LIQUID BIOPSY; IMMUNE-CHECKPOINTS; METASTATIC NSCLC; OPEN-LABEL; T-CELLS; MUTATION; DNA;

D O I：

10.1016/j.critrevonc.2020.102948

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the highly dynamic field of advanced malignancies, biomarkers from liquid samples are urgently needed to improve treatment tailoring. However, the heterogenic data lack direct comparison of assays, vectors and re-levant validations are rarely found. Therefore, we classified the available studies based on three categories: Measured vectors, applied technique and detected biomarker. High blood tumor mutational burden and low baseline levels of soluble programmed cell death 1 ligand 1 (PD-L1) appear to predict treatment responses to immunotherapy. A high PD-1(+) CD4(+) T-cell count was asso-ciated with poor overall survival, PD-1(+)CD8(+) T-cells connect to a favorable outcome. Circulating tumor cells expressing PD-L1 were mainly associated with poor overall survival and treatment failure. Conclusion: Measurement of immunological factors as liquid biomarkers is feasible and has shown promising results. The use of coherent nomenclatures, cross-platform assay comparisons and validations through appropriate powered clinical trials are urgently required to push this auspicious field.

引用

页数：12

共 104 条

[61] Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist [J].